Control of arthritis pain with anti-nerve-growth factor: Risk and benefit

Matthias F. Seidel, Nancy E Lane

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nervegrowth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin generelated peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.

Original languageEnglish (US)
Pages (from-to)583-588
Number of pages6
JournalCurrent Rheumatology Reports
Issue number6
StatePublished - Dec 2012


  • Antagonists
  • Arthritis
  • Benefit
  • Nerve-growth factor
  • Neurogenic inflammation
  • NGF
  • Pain
  • Receptor antagonists
  • Rheumaticdiseases
  • Risk

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Control of arthritis pain with anti-nerve-growth factor: Risk and benefit'. Together they form a unique fingerprint.

Cite this